Making the Pitch. Norma Biln, BSc, MBA CEO, Augurex Life Sciences Corp. May 13, 2017

Transcription

1 Making the Pitch Nrma Biln, BSc, MBA CEO, Augurex Life Sciences Crp. May 13, 2017

2 What we will review Tday 1. What ges int a winning pitch 2. Refining and perfecting yur pitch Preparatin Presentatin Structure PwerPint tips 3. Examples f winning cntent

3

4 It all cmes dwn t 1. The Peple have what it takes 2. The Market has a high unmet need 3. The Technlgy prvides a unique slutin in that rder r imprtance Hw will yur cmpany be viable and deliver sharehlder value

5 Where s the Exit?

6 Organizing Cntent fr the Pitch 12 Questins in Rund 3 The Prduct Market Scpe Market Need Dist Channels (Flw) Intellectual Prperty Tech Develpment Stage The Cmpetitin Barriers t Cmpetitin Technlgical Team Management Capacity Business Plan Status Financial Psitin

7 Preparatin: 80% f the Win Hw well yu present tells the NVBC Jury hw CLEAR yu are n the critical success factrs CONVINCING yu are t stakehlders INTERESTED investrs will be in yur venture Managing the Q&A is as imprtant as the PITCH Knw yur audience The difference between first and secnd place is nly 3% -Brian Tracy

8 Slide Structure 15 Minute Pitch, 25 Min Q&A Main Deck: 10 slides The Peple: 1 r 2 The Market: 4 r 5 The Technlgy: 4 r 5 First and Last Slide f the Main Deck First Slide: Tell them what yu are ging t cnvince them f Last Slide: Summarize the winning cmpnents f yur venture Back-up Deck: slides Technical details/diagrams, PtenJal Risks/SWOT analysis Next Steps, Deal Scenaris/Analgues, AssumpJns Slide Frmat Use as many images as pssible Maximum 6 majr bullets per slide and 6 wrds per bullet

9

10 Presentatin Management Management f Time 1-2 minutes per slide PracJce simplifying the cmplex SJcking t the Jme is crijcal Clear thinkers are succinct and t the pint Prfessinal, capable peple respect Jme Yu want yur whle stry t be delivered Wh shuld be the Presenter The persn wh is leading the cmpany

11 Presentatin Skills Prper Set-Up Using a Laser Pinter Have 1 printut f yur presentajn Slide navigajn and keeping their axenjn PracJce 20 Jmes: and get feedback Limits the number f uhm s Calms yu dwn when yu knw it cld Ensures yu stay n Jme PresentaJn Tips Dress well and make eye-cntact Make reference t Jurr s quesjns Never get t relaxed

12 Key Slides frm the Augurex Winning Deck

13 The Peple Cmpetency Checklist Management! Nrma Biln, BSc MBA CEO and C-funder Anthny MarAa, PhD CSO and C-funder Eric Adams, BSc MIBS CEO and President, EnGene Strategic Advisrs! Sage Baker, MBA VP, IR & Crprate CmmunicaJns, Aspreva Rbert Bryan, PhD Frmer VP, Research & Develpment, ID Bimedical Gardiner Smith, BA JD Special Cunsel, Bwles Rice McDavid Graff & Lve Advisr Agreements, Frmal Time Cmmitment, Milestne Based Equity Cmpensatin!

14 The Bimarker Market in its infancy with high grwth ptenjal Supprt frm Capital Markets Regulatrs FDA Market Influences Patented Bimarkers with MulJple ApplicaJns PsiJve Market Influences High Chances f Success (lwer risk than pharma) Start-up Cmpanies Abundance f Early-Stage Technlgies RelaJvely Shrt Develpment Life-Cycle Fragmented Market Less Capital Intensive Lwer Burn-Rate Industry CnslidaJn

15 PtenJal Partners and CmpeJtrs Dade Behring Arthritis Diagnstics Anti-TNF and Rx in develpment UCB GSK Wyeth/Amgen Centcr/Schering Plugh Eli-Lilly Zeus Scientific Inva Bristl Myers Squibb Diamedix Abbtt Rche Orth- Clinical (J&J) Axis-Shield Bayer Beckman Culter Bectn Dickinsn General Diagnstics Surce: FDA database and Datamnitr syndicated market reprts!

16 Key Risks (Back Deck Slide) Technical Risks Feasibility f TesJng/Tl Develpment PtenJal that larger sample size tesjng desn t supprt current findings IP Risk PCT Publishes in Nvember PtenJal blcking f FTO between nw and then StaJsJcal Risk May require larger sample sizes t shw significance alng chrts with addijnal data Cmmercial Risk Current partner discussins may nt slidify Financial Risk MiJgaJng the abve risks may require addijnal financing 16!

17 Deal Opprtunity Size 67X Peak Year Sales (year 7) $892M EBITDA (benchmark fr NPV calc) 29% Discunt Rate 15% Prduct NPV - Base Case $870M Augurex Net RyalJes 7% Out-license deal NPV $202 M If the Target Raise is $1.5 M fr 50% f the cmpany and we d a $202M deal, sharehlders get $101M which equates t a 67X return Surce: "EBITDA average f BiSite, Myriad, Axis-Shield, Adeza, Cytyc "Estimated sublicense ryalty rates: Ryalty Surce IP Database!

18